Astellas Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Astellas Pharma sits in the top decile of US sponsors by registered trial count (#179 of 15,742 sponsors by registered trial count).
Astellas Pharma: 165 sponsored US clinical trials, 2 recruiting.
Astellas Pharma sponsors 165 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 143 completed. 47 of these trials are in Phase 3-4 (later-stage) and 113 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Candidemia, with 4 trials.
Top-decile sponsor footprint
Astellas Pharma ranks in the top decile of sponsors by registered trial count (#179 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
143 of 162 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
165 total, page 2 of 4
A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects
NCT01088919
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
NCT01009775
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
NCT01007292
A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
NCT01016054
Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers
NCT01015040
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
NCT00889382
Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers
NCT01430065
Study of the Effect of Food on the Pharmacokinetics of Mirabegron
NCT00939757
Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy Volunteers
NCT01364987
Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron
NCT00940121
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00912964
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
NCT00808223
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
NCT00902291
A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
NCT00863707
A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
NCT00862641
Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
NCT00826280
Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers
NCT00870441
A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults
NCT00850746
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K
NCT01364974
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
NCT00739453
A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.
NCT00790660
Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers
NCT00776516
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer
NCT00816764
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer
NCT00816686
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
NCT00750620
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K
NCT01387087
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
NCT00698243
A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery
NCT00595426
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00688688
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
NCT00634049
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00662909
A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers
NCT00653822
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
NCT00543569
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
NCT00603356
A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant
NCT00606268
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
NCT00608335
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
NCT00607763
AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
NCT00519233
Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life
NCT00573508
An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates
NCT00818584
Study of Intermittent OSI-906 Dosing
NCT00514306
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
NCT00493324
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
NCT00486200
Study of Continuous OSI-906 Dosing
NCT00514007
Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
NCT00507455
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
NCT00498914
An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
NCT00514267
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
NCT00413218
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
NCT00412893
A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
NCT00410514
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 59 |
| Phase 2 | 54 |
| Phase 3 | 28 |
| Phase 4 | 19 |
Therapeutic Areas
What is open in the Astellas Pharma pipeline
2 recruiting of 165 indexed (1% open); 143 completed (87%).
Phase mix: 47 late (III/IV) vs 113 early (I/II) (early-phase heavy).
Top condition: Candidemia (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Astellas Pharma: open-pipeline peers nationwide
Peers matched on 165 registered trials and 1% open enrollment, not the therapeutic-area sidebar.
Astellas Pharma sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 165 trials (± recruiting share)
- Teva Branded Pharmaceutical Products R&D · 167 trials · 4% recruiting
- Wyeth is now a wholly owned subsidiary of Pfizer · 167 trials · 0% recruiting
- Temple University · 163 trials · 13% recruiting
- Tufts University · 163 trials · 6% recruiting
Sponsors near 1% open enrollment (± trial volume)
- University of New Mexico · 1% recruiting · 168 trials
- Abbott Nutrition · 1% recruiting · 89 trials
- Baxalta now part of Shire · 1% recruiting · 74 trials
- Power Life Sciences · 2% recruiting · 62 trials
Related
What to do with this Astellas Pharma page
165 registered trials is a research-attention snapshot, not an endorsement of Astellas Pharma or any single study.
- 2 of Astellas Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Candidemia is the condition Astellas Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Candidemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Astellas Pharma pipeline card: 165 registered trials from official public datasets.Report a data error.